89bio, Inc. (NASDAQ: ETNB)
$6.2600
-0.0500 ( -1.42% ) 330.9K
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Market Data
Open
$6.2600
Previous close
$6.3100
Volume
330.9K
Market cap
$739.59M
Day range
$6.1890 - $6.6200
52 week range
$6.1516 - $16.6300
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 15 | May 09, 2024 |
| 4 | Insider transactions | 1 | May 03, 2024 |
| 3 | Insider transactions | 2 | Apr 23, 2024 |
| ars | Annual reports | 1 | Apr 19, 2024 |
| 8-k | 8K-related | 15 | Apr 17, 2024 |
| def | Proxies and info statements | 6 | Apr 17, 2024 |
| 4 | Insider transactions | 1 | Apr 15, 2024 |
| 8-k | 8K-related | 13 | Apr 10, 2024 |
| 4 | Insider transactions | 1 | Apr 03, 2024 |
| 4 | Insider transactions | 1 | Mar 06, 2024 |